The main purpose of this study is to examine how AZD6140 affects patients with severe kidney disease compared to volunteers with normal kidneys. Subjects in the study will receive one dose of AZD6140.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Enrollment
24
single oral dose
Research Site
Phoenix, Arizona, United States
Research Site
Anaheim, California, United States
Research Site
Miami, Florida, United States
Research Site
San Antonio, Texas, United States
Blood levels of AZD6140 in patients with severe kidney disease compared to volunteers with normal kidneys
Time frame: Scheduled times during the 3 days after the study drug is taken
Safety and tolerability of AZD6140 in patients with severe kidney disease compared to subjects with normal kidneys
Time frame: Screening through completion of the study
Measure the effect of AZD6140 on how well blood clots in patients with severe kidney disease compared to subjects with normal kidneys
Time frame: Scheduled times during the 3 days after the study drug is taken
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.